Kursrakete NOVA BIOGENETICS - 500 Beiträge pro Seite

[Stammzelle]

Eine Wahnsinnsperformance legt derzeit die NOVA BIOGENETICS, die unter dem Kürzel NVBG OTC-Wert in New York gehandelt wird, hin.
Beobachte die Aktie, seit sie vor einigen Wochen an einem Tage von 0,19 auf über 0,4 USD

[Stammzelle]

Eine Wahnsinnsperformance legt derzeit die NOVA BIOGENETICS, die unter dem Kürzel NVBG OTC-Wert in New York gehandelt wird, hin.
Beobachte die Aktie, seit sie vor einigen Wochen an einem Tage von 0,19 auf über 0,4 USD gehüpft ist.
Habe leider keine News finden können, die einen derartigen Kuranstieg erahnen ließen.
Auf der Homepage www.novabiogenetics ist nachzulesen, dass das Unternehmen an der Herstellung von antibiotischen Stoffen forscht.
Wer weiß mehr über die Firma, deren Aktien meines Wissens nach nicht in Deutschland handelbar sind?

Gruß Stammzelle

[js200]

03/24/2005 (10:30 ET) NVBG: Volume Spike; 21% > 20-adsv, Stock +24.32% - Knobias
03/24/2005 (10:01 ET) NVBG: New 52-Wk High @ $2.450 up 32.43% - Knobias
03/23/2005 (11:03 ET) NVBG: Volume Spike; 70% > 20-adsv, Stock +33.33% - Knobias
03/23/2005 (11:02 ET) NVBG: New 52-Wk High @ $2.220 up 48.00% - Knobias

JS200

[js200]

Nova BioGenetics Announces Sales for Month of October; Sales Exceeds Entire Fiscal Year 2004

Monday , November 01, 2004 13:02 ET

ATLANTA, Nov 1, 2004 (BUSINESS WIRE) -- Nova BioGenetics (OTCBB: NVBG), an Atlanta-based biotech holding company, released sales figures for the month of October 2004. The announcement is significant as the sales generated by the specialty division of the company exceed the entire amount sold by the same division for the entire fiscal year of 2004. The total amount sold in the month of October was $274,956.14; in comparison, to the entire fiscal year of 2004 was just $261,881.00. Sales increase was primarily attributable to the work of the company in developing long term relationships with multi-national companies.

NVBG reminds all shareholders to review the company`s corporate filings with the SEC as to determine the investment opportunity in the company`s stock. There can be no guarantee that sales will continue at this same level and each investor should make their own determination when purchasing penny stock.

About: Nova Biogenetics

At Nova BioGenetics, the pursuit of new ideas to improve and solidify business relationships has always been paramount. We constantly strive to set new standards for quality, integrity and efficiency in all of our affairs. Our innovations have propelled us forward into the antimicrobial and antibiotic research

From a infrastructure that stretches around the globe, we serve strategic customers in many countries in diverse markets including biopharmaceuticals, paints, coatings, healthcare applications, textiles, concrete, lubricants, anti-stats and filtration. We`re proud of our pioneering research and development into the market`s only soy/corn-based antimicrobial technology, which serves a dual purpose by providing a solution to clients while safeguarding our environment.

Through a dynamic network of synergistic partnerships, we help the world`s leading company`s debut exciting, cutting-edge products that are built upon a framework of quality, safety and reliability. We also manage and oversee strategically located Master Licensees, which ensures conformity and adherence to our environmental commitments pertaining to our specialty chemical products.

Further information on NVBG and its line of products can be found by visiting the firm`s web site at http://www.novabiogenetics.com, or by calling 1-770-650-6508. Eric Heinen.

Safe Harbor/Forward-looking Statements:

Statements in this news release that are not historical are forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company. These areas include: developing technologies, dependence on collaborative partners, the inherent complexity and uncertainty regarding he development of products, early-stage development of NVBG, the result of research and development efforts; future capital needs, uncertainty of additional funding; government regulations and other factors which are detailed in the company`s periodic reports and registration statements filed with the Securities and Exchange Commission. NVBG does not undertake to revise or update any forward-looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of NVBG.

SOURCE: Nova BioGenetics


CONTACT: Nova BioGenetics
Eric Heinen, 770-650-6508
www.novabiogenetics.com



Copyright (C) 2004 Business Wire. All rights reserved.


-0-


KEYWORD: GEORGIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
PRODUCT
Copyright
Business
Wire
2004


STOCK SYMBOLS: [(nvbg)]

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


03/24/2005 (10:30 ET) NVBG: Volume Spike; 21% > 20-adsv, Stock +24.32% - Knobias



03/24/2005 (10:01 ET) NVBG: New 52-Wk High @ $2.450 up 32.43% - Knobias



03/23/2005 (11:03 ET) NVBG: Volume Spike; 70% > 20-adsv, Stock +33.33% - Knobias



03/23/2005 (11:02 ET) NVBG: New 52-Wk High @ $2.220 up 48.00% - Knobias



03/23/2005 (09:02 ET) bullstox.com: Stock Movers and Gainers -- BullStox.com PMHJ, MLXO, NVBG, CNTI - M2 Communications



03/15/2005 (10:40 ET) NVBG: New 52-Wk High @ $0.550 up 14.58% - Knobias



03/14/2005 (13:25 ET) NVBG: New 52-Wk High @ $0.480 up 20.00% - Knobias



03/07/2005 (16:10 ET) NVBG: New 52-Wk High @ $0.450 up 28.57% - Knobias



03/04/2005 (10:21 ET) NVBG: New 52-Wk High @ $0.400 up 17.65% - Knobias



02/25/2005 (10:56 ET) NVBG: New 52-Wk High @ $0.350 up 12.90% - Knobias



02/18/2005 (12:53 ET) NVBG: Filed New Form 10QSB, Quarterly Report - Edgar



02/15/2005 (10:14 ET) NVBG: Filed New Form NT 10-Q, Quarterly Report to be Filed Late - Edgar



01/03/2005 (14:54 ET) NVBG: Schwartz Resigns as CFO, SEC, & TREAS - Knobias



01/03/2005 (14:50 ET) NVBG: Filed New Form 8-K, Material Event Disclosure - Edgar



12/30/2004 (16:12 ET) NVBG: Filed New Form 10QSB/A, Quarterly Report - Edgar



12/21/2004 (17:36 ET) NVBG: Filed New Form 10QSB, Quarterly Report - Edgar



11/16/2004 (10:56 ET) NVBG: Filed New Form NT 10-Q, Quarterly Report to be Filed Late - Knobias



11/01/2004 (13:02 ET) Nova BioGenetics Announces Sales for Month of October; Sales Exceeds Entire Fiscal Year 2004 - Business Wire



10/14/2004 (06:51 ET) NVBG: Filed New Form 10KSB - Edgar



09/29/2004 (16:38 ET) NVBG: Filed New Form 8-K/A - Edgar



09/29/2004 (16:38 ET) NVBG: Filed New Form NT 10-K - Edgar



09/17/2004 (13:24 ET) NVBG: Filed New Form 8-K/A - Edgar



09/02/2004 (15:49 ET) NVBG: Appointment of Bouwhuis Morrill & Co LLC - Knobias



09/02/2004 (15:40 ET) NVBG: Filed New Form 8-K - Edgar


JS200